scholarly journals Risk Factors for Relapse Following Allogeneic Transplant for Acute Myeloid Leukemia in the UCLA Patient Population

2017 ◽  
Vol 23 (3) ◽  
pp. S291-S292
Author(s):  
Harsh Patel ◽  
Alfonso Molina ◽  
Mina Nikanjam ◽  
Gary Schiller
2021 ◽  
Vol 27 (3) ◽  
pp. S150
Author(s):  
Vanessa E Kennedy ◽  
Gavin Hui ◽  
Daria Gaut ◽  
Varun Mittal ◽  
Caspian Oliai ◽  
...  

Author(s):  
Carlo Lajolo ◽  
Rupe Cosimo ◽  
Schiavelli Anna ◽  
Gioco Gioele ◽  
Metafuni Elisabetta ◽  
...  

Background: Saprochaete clavata infection is an emerging issue in immunosuppressed patients, causing fulminant fungaemia. The purpose of this systematic review of cases is to retrieve all cases of S. clavata infection and describe oral lesions as the first manifestation of S. clavata infection. Methods: We report the first case of intraoral S. clavata infection in Acute Myeloid Leukemia (AML) affected subject, presenting as multiple grayish rapidly growing ulcerated swellings, and provide a review of all published cases of infection caused by S. clavata, according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, conducted by searching SCOPUS, Medline, and CENTRAL databases. Only articles in English were considered. Individual patient data were analyzed to identify risk factors for S. clavata infection. Results: Seventeen of 68 retrieved articles were included in the review reporting data on 96 patients (mean age 51.8 years, 57 males and 38 females). Most cases were disseminated (86) with a 60.2% mortality rate. Ninety-five were hematological patients, with AML being the most common (57 cases). Conclusions:S. clavata infection in immunosuppressed patients has a poor prognosis: middle-age patients, male gender and Acute Myeloid Leukemia should be considered risk factors. In immunosuppressed patients, the clinical presentation can be particularly unusual, imposing difficult differential diagnosis, as in the reported case.


2015 ◽  
Vol 56 (7) ◽  
pp. 2193-2195 ◽  
Author(s):  
Kenji Kishimoto ◽  
Ryoji Kobayashi ◽  
Mizuho Ichikawa ◽  
Hirozumi Sano ◽  
Daisuke Suzuki ◽  
...  

Cancer ◽  
2012 ◽  
Vol 118 (18) ◽  
pp. 4589-4596 ◽  
Author(s):  
Sara S. Strom ◽  
Robert Oum ◽  
Kplola Y. Elhor Gbito ◽  
Guillermo Garcia-Manero ◽  
Yuko Yamamura

2000 ◽  
Vol 18 (18) ◽  
pp. 3273-3279 ◽  
Author(s):  
Wing Leung ◽  
Melissa M. Hudson ◽  
Donald K. Strickland ◽  
Sean Phipps ◽  
Deo K. Srivastava ◽  
...  

PURPOSE: To investigate the incidence of and risk factors for late sequelae of treatment in patients who survived for more than 10 years after the diagnosis of childhood acute myeloid leukemia (AML). PATIENTS AND METHODS: Of 77 survivors (median follow-up duration, 16.7 years), 44 (group A) had received chemotherapy, 18 (group B) had received chemotherapy and cranial irradiation, and 15 (group C) had received chemotherapy, total-body irradiation, and allogeneic bone marrow transplantation. Late complications, tobacco use, and health insurance status were assessed. RESULTS: Growth abnormalities were found in 51% of survivors, neurocognitive abnormalities in 30%, transfusion-acquired hepatitis in 28%, endocrine abnormalities in 16%, cataracts in 12%, and cardiac abnormalities in 8%. Younger age at the time of diagnosis or initiation of radiation therapy, higher dose of radiation, and treatment in groups B and C were risk factors for the development of academic difficulties and greater decrease in height Z score. In addition, treatment in group C was a risk factor for a greater decrease in weight Z score and the development of growth-hormone deficiency, hypothyroidism, hypogonadism, infertility, and cataracts. The estimated cumulative risk of a second malignancy at 20 years after diagnosis was 1.8% (95% confidence interval, 0.3% to 11.8%). Twenty-two patients (29%) were smokers, and 11 (14%) had no medical insurance at the time of last follow-up. CONCLUSION: Late sequelae are common in long-term survivors of childhood AML. Our findings should be useful in defining areas for surveillance of and intervention for late sequelae and in assessing the risk of individual late effects on the basis of age and history of treatment.


Sign in / Sign up

Export Citation Format

Share Document